Title {1}	Interleukin-6 Receptor Antibodies (tocilizumab) in Acute Myocardial Infarction with Intermediate to High Risk of Cardiogenic Shock Devel-opment (DOBERMANN-T): Study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial
Trial registration {2a and 2b}.	Regional Ethics Committee: H-21045751. EudraCT: 2021–002028-19. ClinicalTrials.gov: NCT05350592. WHO Universal Trial Number: U1111-1277–8523
Protocol version {3}	Issue date: August 01, 2022. Protocol amendment number: 04.
Funding {4}	External financial grants: Novo Nordisk Foundation. Simon Spies Foundation. Helge Peetz og Verner Peetz og hustru Vilma Peetz Legat. Internal financial grants: Rigshospitalets Apparaturudvalg Rigshospitalets The Heart Centre Research Committee
Author details {5a}	Joakim Bo Kunkel, MD Department of Cardiology The Heart Centre Copenhagen University Hospital—Rigshospitalet Ryesgade 53, 9841, DK-2100 Copenhagen, Denmark E-mail: joakim.bo.kunkel@regionh.dk Phone: + 45 60 60 39 10
Name and contact information for the trial sponsor {5b}	Christian Hassager, MD, DMSc Department of Cardiology The Heart Centre Copenhagen University Hospital—Rigshospitalet Inge Lehmanns Vej 7, DK-2100 Copenhagen, Denmark E-mail: christian.hassager@regionh.dk. Phone: + 45 35 45 05 72
Role of sponsor {5c}	The Sponsor has status as Sponsor-Investigator and is thus directly involved with the initiation, design, and execution of the trial.